Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Natriuretic peptides as biomarkers in heart failure.J Investig Med. 2013; 61: 950-955
- Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction.Circulation. 2002; 106: 2961-2966
- Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells.Eur J Biochem. 1999; 264: 397-406
- Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling.Circ Heart Fail. 2009; 2: 684-691
- IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.J Clin Invest. 2007; 117: 1538-1549
- Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load.J Am Coll Cardiol. 2008; 52: 2166-2174
- Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma — the Presage ST2 assay.Clin Chim Acta. 2009; 409: 33-40
- Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.Clin Chem. 2012; 58: 1673-1681
- Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study.Circulation. 2012; 126: 1596-1604
- Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes.Open Biomark J. 2012; 2012: 1-8
- Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study.J Am Coll Cardiol. 2007; 50: 607-613
- Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease.Am J Clin Pathol. 2008; 130: 578-584
- Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study.Int J Cardiol. 2013; 168: 2186-2194
- Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.J Am Coll Cardiol. 2008; 52: 1458-1465
- Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.Am J Cardiol. 2011; 107: 259-267
- Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea.Circ Heart Fail. 2009; 2: 311-319
- Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure.Eur J Heart Fail. 2011; 13: 718-725
- Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure.Clin Chem. 2008; 54: 752-756
- Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure.Cardiology. 2012; 122: 158-166
- Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.J Card Fail. 2008; 14: 732-738
- Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy.Crit Care. 2012; 16: R135
- Association of ST2 levels with cardiac structure and function and mortality in outpatients.Am Heart J. 2010; 160: 721-728
- High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure.Circ Heart Fail. 2011; 4: 180-187
- Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure.Rev Esp Cardiol. 2010; 63: 1171-1178
- Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology.Eur J Heart Fail. 2012; 14: 268-277
- Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure.Eur J Heart Fail. 2012; 14: 32-38
- Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.J Am Coll Cardiol. 2009; 54: 2174-2179
- Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.Clin Chem. 2012; 58: 257-266
- Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.Circulation. 2008; 117: 1936-1944
- Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.J Am Coll Cardiol. 2010; 55: 243-250
- Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.Circulation. 2004; 110: 3121-3128
- Galectin-3 mediates aldosterone-induced vascular fibrosis.Arterioscler Thromb Vasc Biol. 2013; 33: 67-75
- Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.Circ Heart Fail. 2013; 6: 107-117
- Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?.Clin Biochem. 2012; 45: 719-726
- Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.J Am Coll Cardiol. 2012; 60: 1249-1256
- Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.J Am Coll Cardiol. 2006; 48: 1217-1224
- Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure.Eur J Heart Fail. 2010; 12: 826-832
- The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.Clin Chim Acta. 2009; 409: 96-99
- Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.Circ Heart Fail. 2013; 6: 219-226
- Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.Eur J Heart Fail. 2013; 15: 511-518
- The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Am Heart J. 2012; 164: 878-883
- Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.Clin Res Cardiol. 2010; 99: 323-328
- Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.Circ Heart Fail. 2012; 5: 72-78
- Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.Eur J Heart Fail. 2013; 15: 1157-1163
- Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.Clin Res Cardiol. 2013; 102: 103-110
- Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.Am J Cardiol. 2011; 108: 385-390
- Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Ann Med. 2011; 43: 60-68
- Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.Eur J Heart Fail. 2012; 14: 74-81
- The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices.J Heart Lung Transplant. 2013; 32: 221-230
Article info
Publication history
Published online: January 16, 2014
Footnotes
Disclosures: Dr J.L. Januzzi reports having received grant support and/or consulting income from Roche Diagnostics, Siemens, Critical Diagnostics, BG Medicine, Thermo Fisher, Singulex, Amgen, Zensun, and Novartis.
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
